Jazz Pharmaceuticals Presents 18 Abstracts at SLEEP 2021

jazz sleep 2021

Jazz Pharmaceuticals plc announced that 13 abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021, the 35th annual meeting of the Associated Professional Sleep Societies (APSS) from June 10-13, 2021.

“Jazz continues to be committed to deepening our understanding of sleep disorders and delivering transformational medicines to those with lifelong and chronic sleep conditions,” said Robert Iannone, M.D., M.S.C.E., executive vice president, research and development and chief medical officer of Jazz Pharmaceuticals. “There remains a large unmet need for people living with sleep disorders, including narcolepsy and idiopathic hypersomnia, and we look forward to showcasing the latest research and results from our portfolio during SLEEP 2021 as we work to help people with sleep disorders live fuller lives.”

Highlights from Jazz at SLEEP 2021 will include the following presentations:

  • A late-breaking abstract poster presentation on June 13 on a sub-group analysis of Xywav™ (calcium, magnesium, potassium and sodium oxybates) oral solution compared to placebo in adults with idiopathic hypersomnia with long sleep time (n=25) and without long sleep time (n=91), and the importance of treatment effects on those two groups
  • Additional data results from the Phase 3, placebo-controlled, double-blind, randomized withdrawal study of Xywav in adults with idiopathic hypersomnia including an oral presentation of the correlation of the idiopathic hypersomnia severity scale score with other measures of sleep parameters
  • Results from a real-world study of the cardiovascular burden of narcolepsy
  • Data results from the titration and administration (START) study of Sunosi® (solriamfetol) in patients with narcolepsy

Xywav is not currently approved by regulatory authorities for the treatment of idiopathic hypersomnia.

The SLEEP 2021 presentations and exhibit hall are available for registered attendees through November 30, 2021 at www.sleepmeeting.org.

Find a full list of Jazz-supported data below:

Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution Oral Presentation and Posters                                      

Presentation Title Author Presentation Date / Time (EDT) & Number
Correlation of the Idiopathic Hypersomnia Severity Scale Score With Other Measures of Sleep Parameters in a Phase 3 Trial Dauvilliers et al. Oral Presentation

 

Sunday, June 13

12:41-12:52 PM

 

Abstract ID: 500

Placebo-Controlled, Double-Blind, Randomized Withdrawal Study of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia Dauvilliers et al. ePoster Presentation

 

Abstract ID: 494

Efficacy and Safety of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia: With and Without Long Sleep Time Bogan et al. ePoster Presentation

 

Abstract ID: LBA070

Effect of Lower-Sodium Oxybate on Sleep Inertia in Idiopathic Hypersomnia in a Double-Blind, Randomized Withdrawal Study Bogan et al. ePoster Presentation

 

Abstract ID: 487

Efficacy and Safety of Once- and Twice-Nightly Dosing of Lower-Sodium Oxybate in Adults With Idiopathic Hypersomnia Arnulf et al. ePoster Presentation

 

Abstract ID: 485

Efficacy of Lower-Sodium Oxybate on Idiopathic Hypersomnia, Measured by the Idiopathic Hypersomnia Severity Scale Foldvary-Schaefer

et al.

ePoster Presentation

 

Abstract ID: 495

Clinical Presentation Prior to Idiopathic Hypersomnia Diagnosis Among US Adults: A Retrospective, Real-World Claims Analysis Saad et al. ePoster Presentation

 

Abstract ID: 497

Utilization of Diagnostic Sleep Testing Prior to Idiopathic Hypersomnia Diagnosis Among US Adults: A Real-World Claims Analysis Saad et al. ePoster Presentation

 

Abstract ID: 499

Timing and Duration of Adverse Events in a Clinical Trial of Lower-Sodium Oxybate in Participants With Narcolepsy With Cataplexy Bogan et al.

 

ePoster Presentation

 

Abstract ID: 486

Cardio-Vascular Burden of Narcolepsy Disease (CV-BOND): A Real-World Evidence Study Ben-Joseph et al. ePoster Presentation

 

Abstract ID: 503

Sunosi® (solriamfetol) Poster Presentations

Presentation Title Author Presentation Number
Solriamfetol Titration & Administration (START): Characteristics of Patients With Narcolepsy and Solriamfetol Prescriber Rationale Thorpy et al. ePoster Presentation

 

Abstract ID: 481

Solriamfetol Titration & Administration (START): Dosing and Titration Strategies in Patients With Narcolepsy Starting Solriamfetol Thorpy et al. ePoster Presentation

 

Abstract ID: 482

Solriamfetol Titration & Administration (START): Physician Titration Strategies in a Hypothetical Patient With Narcolepsy Singh et al. ePoster Presentation

 

Abstract ID: 484

Additionally, data from the following investigator-sponsored trials will be presented as poster presentations:

Presentation Title Author Presentation Number
Impact of A Single Sleep Education Session on Beliefs and Attitudes Among People with Excessive Daytime Sleepiness: A Pilot Study Grandner et al. ePoster Presentation

 

Abstract ID: 089

Strategies for Dealing with or Ameliorating Excessive Sleepiness: Beliefs and Attitudes of People with Daytime Sleepiness Grandner et al. ePoster Presentation

 

Abstract ID: 090

Seeking Treatment for Daytime Sleepiness: Beliefs and Attitudes Among People with Excessive Daytime Sleepiness Grandner et al. ePoster Presentation

 

Abstract ID: 120

It Makes Relationships Harder: The Role of Narcolepsy in Social and Romantic Relationships in Young Adults Zhou et al. ePoster Presentation

 

Abstract ID: 498

The Effect of Sodium Oxybate on Cataplexy in Orexin -/- Mice Hamieh et al ePoster Presentation

 

Abstract ID: 006

Source: Jazz Pharmaceuticals

Be the first to comment

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.